GlassScriptPhysician profile
Manish B Undavia
NPI 1013042944
$39,985.55
in general payments reported to CMS, 2019-2025
18 companies · $9,587 in 2025
The $9,587 reported for 2025 was more than what 79% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,543 · 2020: $1,850 · 2021: $5,560 · 2022: $5,076 · 2023: $4,649 · 2024: $6,720 · 2025: $9,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Travel and Lodging: $2,852 · Consulting Fee: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,854.01 |
| Travel and Lodging | $2,852.44 |
| Consulting Fee | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,888.86 | 2019-2025 | Emblem Mri S-Icd, General - Therapies, Resonate El Icd Vr |
| Medtronic, INC. | $8,285.53 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Micra |
| Biosense Webster, INC. | $6,093.35 | 2019-2025 | Carto 3, Qdot Micro Catheter, Nuvision Ice Catheter |
| Pfizer INC. | $5,653.14 | 2019-2025 | |
| Abbott Laboratories | $3,825.75 | 2019-2025 | Aveir, Amplatzer Amulet, Jot Dx |
| Biotronik INC. | $3,064.98 | 2019-2025 | Acticor 7 Vr-T Dx, Edora 8 Dr-T, Rivacor 7 Dr-T |
| Medtronic Vascular, INC. | $1,543.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $1,150.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $577.89 | 2019-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $243.79 | 2021-2022 | |
| Cardiva Medical, INC. | $169.30 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Janssen Pharmaceuticals, INC | $145.69 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $109.85 | 2024-2025 | |
| Cordis US Corp. | $84.38 | 2025 | Mynx Control Venous |
| Merck Sharp & Dohme LLC | $66.16 | 2022-2025 | Verquvo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.42 | 2025 | Repatha, Repatha |
| Novo Nordisk INC | $24.38 | 2025 | Ozempic |
| Ethicon US, LLC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Undavia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.